HK1048817B - Hiv replication inhibiting pyrimidines - Google Patents

Hiv replication inhibiting pyrimidines Download PDF

Info

Publication number
HK1048817B
HK1048817B HK03101063.7A HK03101063A HK1048817B HK 1048817 B HK1048817 B HK 1048817B HK 03101063 A HK03101063 A HK 03101063A HK 1048817 B HK1048817 B HK 1048817B
Authority
HK
Hong Kong
Prior art keywords
alkyl
amino
substituted
cyano
formula
Prior art date
Application number
HK03101063.7A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1048817A1 (en
Inventor
Bart De Cort
Marc Rene De Jonge
Jan Heeres
Chih Yung Ho
Paul Andriaan Jan Janssen
Robert W. Kavash
Lucien Maria Henricus Koymans
Michael Joseph Kukla
Donald William Ludovici
Koen Jeanne Alfons Van Aken
Koenraad Jozef Lodewijk Marcel Andries
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26805159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1048817(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HK1048817A1 publication Critical patent/HK1048817A1/en
Publication of HK1048817B publication Critical patent/HK1048817B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK03101063.7A 1998-11-10 2003-02-14 Hiv replication inhibiting pyrimidines HK1048817B (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10779298P 1998-11-10 1998-11-10
US107792P 1998-11-10
US14396299P 1999-07-15 1999-07-15
US143962P 1999-07-15
PCT/EP1999/007417 WO2000027825A1 (en) 1998-11-10 1999-09-24 Hiv replication inhibiting pyrimidines
WOPCT/EP99/07417 1999-09-24

Publications (2)

Publication Number Publication Date
HK1048817A1 HK1048817A1 (en) 2003-04-17
HK1048817B true HK1048817B (en) 2010-04-09

Family

ID=26805159

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03101063.7A HK1048817B (en) 1998-11-10 2003-02-14 Hiv replication inhibiting pyrimidines

Country Status (41)

Country Link
US (5) US6878717B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP1002795B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3635238B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100658489B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1214013C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP1683A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR024227A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (2) ATE455107T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU762523C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG65103B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI9915552B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2350801C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY2008021I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ301367B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE69905683T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1002795T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA004049B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE05086B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2193664T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR09C0004I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1048817B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (2) HRP20010161B9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HU227453B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (1) ID28376A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL143023A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LTC1002795I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91528I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY121108A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300373I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (3) NO318801B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ511116A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA11674A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL204427B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1002795E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1002795T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (2) SK287270B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR200101306T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI238161B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA70966C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2000027825A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200103769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762523C (en) * 1998-11-10 2004-02-12 Janssen Pharmaceutica N.V. HIV replication inhibiting pyrimidines
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
CN1234347C (zh) 1999-09-24 2006-01-04 詹森药业有限公司 抗病毒组合物
ES2306671T3 (es) 1999-10-07 2008-11-16 Amgen Inc. Inhibidores de triazina quinasa.
KR20030024659A (ko) 2000-02-17 2003-03-26 암겐 인코포레이티드 키나제 억제제
AU782948B2 (en) 2000-05-08 2005-09-15 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
CA2406562C (en) 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
US7418471B2 (en) * 2000-11-01 2008-08-26 Snapnames.Com, Inc. Domain name acquisition and management system and method
EP1392662B1 (de) 2001-05-29 2009-01-07 Bayer Schering Pharma Aktiengesellschaft Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
UY27487A1 (es) * 2001-10-17 2003-05-30 Boehringer Ingelheim Pharma Derivados de pirimidina, medicamentos que contienen estos compuestos, su empleo y procedimiento para su preparación
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
EA010859B1 (ru) 2001-11-01 2008-12-30 Янссен Фармацевтика Н.В. Гетероариламины - производные пиримидина и пиридазина в качестве ингибиторов гликогенсинтаза-киназы 3-бета (ингибиторов gsk3)
IL161661A0 (en) 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv Amide derivatives as glycogen synthase kinase 3-beta inhibitors
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003218736B2 (en) 2002-03-13 2009-01-08 Janssen Pharmaceutica N.V. New inhibitors of histone deacetylase
CN1305850C (zh) 2002-03-13 2007-03-21 詹森药业有限公司 作为组蛋白脱乙酰酶新颖抑制剂的磺酰基氨基衍生物
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003093344A1 (en) * 2002-05-03 2003-11-13 Janssen Pharmaceutica N.V. Polymeric microemulsions
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
TW200409629A (en) 2002-06-27 2004-06-16 Bristol Myers Squibb Co 2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
NZ537752A (en) 2002-07-29 2006-12-22 Rigel Pharmaceuticals Inc Use of 2,4-pyrimidinediamine compounds in the preparation of medicaments for treating autoimmune diseases
NZ538611A (en) 2002-08-09 2007-03-30 Janssen Pharmaceutica Nv Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
EP2422772A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
JP2006508997A (ja) * 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用
HRP20050696B1 (en) 2003-01-14 2008-10-31 Arena Pharmaceuticals Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
JP4783725B2 (ja) 2003-02-07 2011-09-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖを阻害する１，２，４−トリアジン
JP5602333B2 (ja) 2003-02-07 2014-10-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ感染の予防のためのピリミジン誘導体
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
ES2325440T3 (es) 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
DK1648467T3 (en) * 2003-07-17 2018-06-25 Janssen Sciences Ireland Uc PROCEDURE FOR MANUFACTURING PARTICLES CONTAINING AN ANTIVIRUS AGENT
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
US8026245B2 (en) * 2003-09-25 2011-09-27 Janssen Pharmaceutica N.V. HIV replication inhibiting purine derivatives
US8099262B2 (en) 2004-03-02 2012-01-17 Virco Bvba Estimation of clinical cut-offs
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
SG156687A1 (en) 2004-07-28 2009-11-26 Janssen Pharmaceutica Nv Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
CN101035773B (zh) 2004-08-10 2012-06-06 詹森药业有限公司 抑制hiv的1,2,4-三嗪-6-酮衍生物
KR20070057798A (ko) * 2004-09-30 2007-06-07 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 저해하는 5-탄소환 또는 복소환으로 치환된피리미딘
BRPI0516746A (pt) * 2004-09-30 2008-09-23 Tibotec Pharm Ltd 5-heterociclil pirimidinas para inibição de hiv
RU2410379C2 (ru) * 2004-09-30 2011-01-27 Тиботек Фармасьютикалз Лтд. 5-замещенные пиримидины, ингибирующие вич
CA2577588C (en) 2004-10-29 2013-09-10 Tibotec Pharmaceuticals Ltd. Hiv inhibiting bicyclic pyrimidine derivatives
WO2006052373A2 (en) * 2004-11-08 2006-05-18 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and etravirine
JP5095409B2 (ja) 2004-11-24 2012-12-12 ライジェル ファーマシューティカルズ， インコーポレイテッド スピロ２，４−ピリミジンジアミン化合物およびその使用
MX2007007189A (es) 2005-01-19 2010-09-28 Rigel Pharmaceuticals Inc Prodrogas de compuestos de 2,4-pirimidindiamina y sus usos.
CA2599228C (en) 2005-01-27 2014-05-13 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 2-( 4-cyanophenylamino) pyrimidine derivatives
DE602006001515D1 (de) 2005-02-16 2008-07-31 Astrazeneca Ab Chemische verbindungen
WO2006087387A1 (en) * 2005-02-18 2006-08-24 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives
CN101133038B (zh) * 2005-03-04 2012-06-27 泰博特克药品有限公司 抑制hiv的2-(4-氰基苯基)-6-羟氨基嘧啶
MX2007014328A (es) 2005-05-16 2008-02-12 Astrazeneca Ab Compuestos quimicos.
US8101752B2 (en) * 2005-05-26 2012-01-24 Tibotec Pharmaceuticals Ltd. Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitrile
MX286273B (es) 2005-06-08 2011-05-04 Rigel Pharmaceuticals Inc Composiciones y metodos para inhibicion de la via jak.
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP1945208A4 (en) * 2005-10-06 2011-08-03 Univ Massachusetts Composition and synthesis of new reagents for inhibition of hiv replication
AU2006307657B2 (en) 2005-10-28 2010-10-28 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
ES2396986T3 (es) 2006-01-19 2013-03-01 Janssen Pharmaceutica N.V. Derivados de piridina y pirimidina como inhibidores de histona desacetilasa
US7834025B2 (en) 2006-01-19 2010-11-16 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
RS51191B (sr) 2006-01-19 2010-10-31 Janssen Pharmaceutica N.V. Derivati aminofenila kao novi inhibitori histon deacetilaze
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CA2645959C (en) 2006-03-30 2016-05-17 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines
EP2004632B1 (en) 2006-03-30 2014-03-12 Janssen R&D Ireland Hiv inhibiting 5-amido substituted pyrimidines
AR060890A1 (es) 2006-05-15 2008-07-23 Boehringer Ingelheim Int Compuestos derivados de pirimidina y composicion farmaceutica en base a ellos
RU2406502C2 (ru) * 2006-06-06 2010-12-20 Тиботек Фармасьютикалз Лтд. Способ получения препаратов тмс125, полученных сушкой распылением
NZ573757A (en) 2006-06-19 2011-11-25 Alpharma Inc Coated multilayer oral dosage forms of naltrexone hydrochloride
AU2007322269A1 (en) * 2006-10-11 2008-05-29 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
WO2008068299A2 (en) 2006-12-06 2008-06-12 Tibotec Pharmaceuticals Ltd. Hydrobromide salt of an anti-hiv compound
JP5283633B2 (ja) 2006-12-29 2013-09-04 テイボテク・フアーマシユーチカルズ Ｈｉｖ阻害性５，６−置換ピリミジン
WO2008080964A1 (en) 2006-12-29 2008-07-10 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 6-substituted pyrimidines
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
EP2212298B1 (en) 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
EP2224805A4 (en) * 2007-12-17 2013-10-16 Alpharma Pharmaceuticals Llc PHARMACEUTICAL COMPOSITION
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
NO2300013T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2008-05-21 2018-02-03
EP2361248B1 (en) 2008-06-27 2018-09-19 Celgene CAR LLC Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
TW201016676A (en) * 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
EA024299B1 (ru) 2009-03-30 2016-09-30 Янссен Сайенсиз Айрлэнд Юси Сокристалл этравирина и никотинамида, способ его получения и применение
WO2010129053A2 (en) 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
WO2010131118A2 (en) * 2009-05-12 2010-11-18 Pliva Hrvatska D.O.O. Polymorphs of etravirine and processes for preparation thereof
US20110196156A1 (en) * 2009-06-22 2011-08-11 Mukund Keshav Gurjar Process for synthesis of diarylpyrimidine non-nucleoside reverse transcriptase inhibitor
WO2011017079A1 (en) 2009-07-27 2011-02-10 Teva Pharmaceutical Industries Ltd. Process for the preparation and purification of etravirine and intermediates thereof
GR1007010B (el) 2009-10-08 2010-10-07 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Ινσουλινοειδη πεπτιδια
SG185641A1 (en) 2010-06-04 2012-12-28 Hoffmann La Roche Aminopyrimidine derivatives as lrrk2 modulators
WO2012001695A1 (en) 2010-06-28 2012-01-05 Hetero Research Foundation A process for etra virine intermediate and polymorphs of etravirine
CN103096716B (zh) 2010-08-10 2016-03-02 西建阿维拉米斯研究公司 Btk抑制剂的苯磺酸盐
KR101871011B1 (ko) 2010-09-22 2018-06-25 아레나 파마슈티칼스, 인크. Ｇｐｒ１１９ 수용체의 조절제 및 그와 관련된 장애의 치료
JP5956999B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
CN103269704B (zh) 2010-11-01 2018-07-06 西建卡尔有限责任公司 杂环化合物和其用途
US8796255B2 (en) 2010-11-10 2014-08-05 Celgene Avilomics Research, Inc Mutant-selective EGFR inhibitors and uses thereof
KR101566091B1 (ko) 2010-11-10 2015-11-04 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체
PL2702045T3 (pl) 2011-04-26 2018-04-30 Mylan Laboratories Ltd. Nowy sposób sporządzania Etrawiryny
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
WO2012170647A1 (en) * 2011-06-09 2012-12-13 Assia Chemical Industriew Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
HUE065564T2 (hu) 2011-08-23 2024-06-28 Libertas Bio Inc Pirimido-piridazinon vegyületek és alkalmazásuk
US20130123498A1 (en) 2011-10-19 2013-05-16 Maja Sepelj MAJER Process for the preparation of etravirine and intermediates in the synthesis thereof
AR088570A1 (es) 2011-10-28 2014-06-18 Celgene Avilomics Res Inc Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
US8703786B2 (en) * 2011-12-07 2014-04-22 Texas Southern University Etravirine formulations and uses thereof
WO2013138502A1 (en) 2012-03-15 2013-09-19 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
JP6317319B2 (ja) 2012-03-15 2018-04-25 セルジーン シーエーアール エルエルシー 上皮成長因子受容体キナーゼ阻害剤の固体形態
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
WO2014068588A2 (en) * 2012-10-29 2014-05-08 Biophore India Pharmaceuticals Pvt. Ltd. Process for the synthesis of etravirine and its intermediates
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
MX2015007945A (es) 2012-12-21 2016-02-16 Verlyx Pharma Inc Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
TW201446745A (zh) 2013-02-08 2014-12-16 Celgene Avilomics Res Inc Ｅｒｋ抑制劑及其用途
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
PT3310760T (pt) 2015-06-22 2022-11-10 Arena Pharm Inc Sal cristalino de l-arginina de ácido (r)-2-(7-(4-ciclopentil-3-(trifluorometil)benziloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para utilização em distúrbios associados a recetores de s1p1
US20190008868A1 (en) 2017-04-28 2019-01-10 Asana Biosciences, Llc Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
CN112601516A (zh) 2018-06-06 2021-04-02 艾尼纳制药公司 治疗与s1p1受体相关的病况的方法
CN110066273A (zh) * 2019-06-05 2019-07-30 山东大学 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
AU2020300619A1 (en) 2019-07-03 2022-01-27 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
CN111217833B (zh) * 2020-02-21 2021-03-16 山东大学 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4659363A (en) * 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
ATE60591T1 (de) * 1984-06-25 1991-02-15 Ciba Geigy Ag Pyrimidinderivate wirksam als schaedlingsbekaempfungsmittel.
KR950006713B1 (ko) 1988-03-31 1995-06-21 미쓰비시 가세이 가부시끼가이샤 6-치환 비환식 피리미딘뉴클레오시드 유도체 및 그 유도체를 유효성분으로 하는 항 비루스제
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
JP2895680B2 (ja) * 1992-07-08 1999-05-24 シャープ株式会社 磁気ヘッドおよびその製造方法
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
RU2153494C2 (ru) * 1993-10-12 2000-07-27 Дзе Дюпон Мерк Фармасьютикал Компани 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CN1198655C (zh) 1995-11-23 2005-04-27 詹森药业有限公司 通过熔体挤出法制备的环糊精固体混合物
KR100219922B1 (ko) * 1996-05-16 1999-09-01 이서봉 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
DE29704863U1 (de) * 1997-03-17 1997-05-22 Gesellschaft für Innenhochdruckverfahren mbH & Co. KG, 73441 Bopfingen Achsschwinge
AU748087B2 (en) 1998-02-17 2002-05-30 Tularik Inc. Anti-viral pyrimidine derivatives
EP0945442A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted pyrimidine derivatives
EP1245567B1 (en) * 1998-03-27 2011-03-02 Janssen Pharmaceutica NV HIV inhibiting pyrimidine derivatives
KR100643419B1 (ko) * 1998-03-27 2006-11-10 얀센 파마슈티카 엔.브이. Ｈｉｖ를 억제하는 피리미딘 유도체
AU762523C (en) * 1998-11-10 2004-02-12 Janssen Pharmaceutica N.V. HIV replication inhibiting pyrimidines
AU782948B2 (en) * 2000-05-08 2005-09-15 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines

Also Published As

Publication number Publication date
KR100658489B1 (ko) 2006-12-18
PL347586A1 (en) 2002-04-08
NO2021015I1 (no) 2021-03-29
NO20011696D0 (no) 2001-04-04
EA004049B1 (ru) 2003-12-25
CY2008021I2 (el) 2010-07-28
CZ20011533A3 (cs) 2001-10-17
AU6200899A (en) 2000-05-29
EA200100536A1 (ru) 2002-02-28
LTPA2008016I1 (lt) 2021-04-26
AU2011200708A1 (en) 2011-03-10
OA11674A (en) 2005-01-12
US20040039005A1 (en) 2004-02-26
US8003789B2 (en) 2011-08-23
NL300373I2 (nl) 2009-04-01
BR9915552A (pt) 2001-08-14
CN1214013C (zh) 2005-08-10
DE122009000003I1 (de) 2009-05-20
ES2193664T3 (es) 2003-11-01
EP1270560A1 (en) 2003-01-02
HRP20080359B1 (hr) 2016-01-01
NZ511116A (en) 2003-08-29
BG65103B1 (bg) 2007-02-28
MY121108A (en) 2005-12-30
JP2002529456A (ja) 2002-09-10
HRP20080359A2 (en) 2008-12-31
US8530655B2 (en) 2013-09-10
US20110263625A1 (en) 2011-10-27
HK1025330A1 (en) 2000-11-10
US6878717B2 (en) 2005-04-12
BG105418A (en) 2001-11-30
ATE455107T1 (de) 2010-01-15
NO20011696L (no) 2001-04-04
EE05086B1 (et) 2008-10-15
AU762523B2 (en) 2003-06-26
TWI238161B (en) 2005-08-21
HU230394B1 (hu) 2016-04-28
KR20010075235A (ko) 2001-08-09
HU227453B1 (en) 2011-06-28
UA70966C2 (uk) 2004-11-15
HK1048817A1 (en) 2003-04-17
HRP20010161B1 (en) 2009-03-31
AU762523C (en) 2004-02-12
NL300373I1 (nl) 2009-03-02
HRP20010161A2 (en) 2002-02-28
US20050288278A1 (en) 2005-12-29
SK287270B6 (sk) 2010-05-07
US20030114472A1 (en) 2003-06-19
SI1002795T1 (en) 2003-10-31
FR09C0004I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2009-02-27
CA2350801C (en) 2008-05-20
DE69905683D1 (de) 2003-04-10
DK1002795T3 (da) 2003-06-30
NO2009003I2 (no) 2010-06-07
PT1002795E (pt) 2003-07-31
PL204427B1 (pl) 2010-01-29
ES2338760T3 (es) 2010-05-12
TR200101306T2 (tr) 2001-10-22
NO318801B1 (no) 2005-05-09
LU91528I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-01-02
SK287269B6 (sk) 2010-05-07
IL169949A (en) 2011-02-28
EP1270560B1 (en) 2010-01-13
US20080176880A1 (en) 2008-07-24
WO2000027825A1 (en) 2000-05-18
HRP20010161B9 (hr) 2014-10-24
US7037917B2 (en) 2006-05-02
AR024227A1 (es) 2002-09-25
DE69905683T2 (de) 2004-03-18
BRPI9915552B8 (pt) 2021-05-25
EP1002795B1 (en) 2003-03-05
EE200100252A (et) 2002-10-15
LTC1002795I2 (lt) 2021-06-10
CY2008021I1 (el) 2010-07-28
IL143023A0 (en) 2002-04-21
EP1002795A1 (en) 2000-05-24
DE69941934D1 (de) 2010-03-04
AP1683A (en) 2006-11-29
JP3635238B2 (ja) 2005-04-06
FR09C0004I2 (fr) 2010-06-11
ID28376A (id) 2001-05-17
CN1322198A (zh) 2001-11-14
ATE233740T1 (de) 2003-03-15
HUP0104177A2 (hu) 2002-03-28
NO2009003I1 (no) 2009-03-09
LU91528I2 (fr) 2009-04-20
HUP0104177A3 (en) 2003-01-28
BR9915552B1 (pt) 2013-11-19
CA2350801A1 (en) 2000-05-18
CZ301367B6 (cs) 2010-02-03
SK6032001A3 (en) 2002-01-07
ZA200103769B (en) 2002-08-12

Similar Documents

Publication Publication Date Title
EP1270560B1 (en) Hiv replication inhibiting pyrimidines
US7015221B2 (en) 2,4-disubstituted triazine derivatives
HK1025330B (en) Hiv replication inhibiting pyrimidines
MXPA01003646A (en) Hiv replication inhibiting pyrimidines
HK1038232B (en) 2,4-disubstituted triazine derivatives with anti hiv activity

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: ADDITION OF INVENTOR: KOENRAAD JOZEF LODEWIJK MARCEL ANDRIES

PE Patent expired

Effective date: 20191031